AI-generated analysis. Always verify with the original filing.
InfuSystem Holdings, Inc. furnished an Investor Presentation under Item 7.01 detailing 2025 financial results including record net revenues of $143.4 million and Adjusted EBITDA of $31.5 million, segment performance, balance sheet strength, and capital allocation including a $20 million share repurchase program. The disclosure provides investors with updated operating and financial metrics through December 31, 2025.
Event Type
Disclosure
Voluntary
Variant
8-K
“Regulation FD Disclosure” of this Current Report on Form 8-K and the Investor Presentation attached hereto as Exhibit 99.1 shall not be deemed “filed” for the
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 InfuSystem Holdings, Inc. Investor Presentation dated February 27, 2026 104 Cover Pa
| Metric | Value | Basis |
|---|---|---|
| Net Revenues | $143.40 | |
| Adjusted EBITDA | $31.50 | Non-GAAP |
| Patient Services Net Revenues | $86.50 | |
| Device Solutions Net Revenues | $56.90 |
Buyback Auth.
$20M program renewed May 20, 2024, expires June 30, 2026; $11.0M purchased as of Dec 31, 2025